ES2891473T3 - Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto - Google Patents
Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto Download PDFInfo
- Publication number
- ES2891473T3 ES2891473T3 ES13733751T ES13733751T ES2891473T3 ES 2891473 T3 ES2891473 T3 ES 2891473T3 ES 13733751 T ES13733751 T ES 13733751T ES 13733751 T ES13733751 T ES 13733751T ES 2891473 T3 ES2891473 T3 ES 2891473T3
- Authority
- ES
- Spain
- Prior art keywords
- baseline
- subject
- mean
- subjects
- approximately
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 106
- 108010074051 C-Reactive Protein Proteins 0.000 title description 102
- 238000000034 method Methods 0.000 title description 34
- 230000035945 sensitivity Effects 0.000 title description 13
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims abstract description 94
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims abstract description 93
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims abstract description 91
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims abstract description 91
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 91
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims abstract description 80
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 66
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims abstract description 46
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 38
- 201000010099 disease Diseases 0.000 claims abstract description 37
- 210000000748 cardiovascular system Anatomy 0.000 claims abstract description 9
- 150000002148 esters Chemical class 0.000 claims abstract description 6
- 150000003839 salts Chemical class 0.000 claims abstract description 4
- SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 claims description 132
- 229920000064 Ethyl eicosapentaenoic acid Polymers 0.000 claims description 95
- 239000002775 capsule Substances 0.000 claims description 41
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 28
- 229930195729 fatty acid Natural products 0.000 claims description 28
- 239000000194 fatty acid Substances 0.000 claims description 28
- 150000004665 fatty acids Chemical class 0.000 claims description 27
- 229960002600 icosapent ethyl Drugs 0.000 claims description 10
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 10
- 108010010803 Gelatin Proteins 0.000 claims description 5
- 239000008273 gelatin Substances 0.000 claims description 5
- 229920000159 gelatin Polymers 0.000 claims description 5
- 235000019322 gelatine Nutrition 0.000 claims description 5
- 235000011852 gelatine desserts Nutrition 0.000 claims description 5
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 27
- 239000000902 placebo Substances 0.000 description 141
- 229940068196 placebo Drugs 0.000 description 141
- 230000008859 change Effects 0.000 description 124
- 108010023302 HDL Cholesterol Proteins 0.000 description 61
- 230000009467 reduction Effects 0.000 description 59
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 58
- 108010028554 LDL Cholesterol Proteins 0.000 description 54
- 230000000694 effects Effects 0.000 description 43
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 42
- 210000003743 erythrocyte Anatomy 0.000 description 33
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 32
- 230000007423 decrease Effects 0.000 description 32
- 238000012216 screening Methods 0.000 description 31
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 30
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 30
- 229960002855 simvastatin Drugs 0.000 description 30
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 30
- 208000035475 disorder Diseases 0.000 description 29
- 230000003993 interaction Effects 0.000 description 28
- 150000002632 lipids Chemical class 0.000 description 26
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 25
- 239000003814 drug Substances 0.000 description 24
- 235000005911 diet Nutrition 0.000 description 22
- 235000012000 cholesterol Nutrition 0.000 description 21
- 229940090949 docosahexaenoic acid Drugs 0.000 description 21
- 229940079593 drug Drugs 0.000 description 21
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 21
- 210000002381 plasma Anatomy 0.000 description 21
- 229960000672 rosuvastatin Drugs 0.000 description 21
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 21
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 20
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 20
- 238000004458 analytical method Methods 0.000 description 20
- 229960005370 atorvastatin Drugs 0.000 description 20
- 230000037213 diet Effects 0.000 description 19
- 210000002966 serum Anatomy 0.000 description 19
- 102000004889 Interleukin-6 Human genes 0.000 description 18
- 108090001005 Interleukin-6 Proteins 0.000 description 18
- 230000002757 inflammatory effect Effects 0.000 description 18
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 16
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 16
- 229940114079 arachidonic acid Drugs 0.000 description 16
- 235000021342 arachidonic acid Nutrition 0.000 description 16
- 108010069201 VLDL Cholesterol Proteins 0.000 description 15
- 238000005259 measurement Methods 0.000 description 15
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 14
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 description 13
- 150000003626 triacylglycerols Chemical class 0.000 description 13
- 239000003550 marker Substances 0.000 description 12
- 239000012528 membrane Substances 0.000 description 12
- 210000004180 plasmocyte Anatomy 0.000 description 12
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 11
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 11
- 108010007622 LDL Lipoproteins Proteins 0.000 description 11
- 102000007330 LDL Lipoproteins Human genes 0.000 description 11
- 229960000815 ezetimibe Drugs 0.000 description 11
- 239000002245 particle Substances 0.000 description 11
- 230000006872 improvement Effects 0.000 description 10
- 230000006641 stabilisation Effects 0.000 description 10
- 238000011105 stabilization Methods 0.000 description 10
- 235000021294 Docosapentaenoic acid Nutrition 0.000 description 9
- 206010022489 Insulin Resistance Diseases 0.000 description 9
- 230000015654 memory Effects 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 230000003936 working memory Effects 0.000 description 9
- 102100032752 C-reactive protein Human genes 0.000 description 8
- 230000001149 cognitive effect Effects 0.000 description 8
- 208000029078 coronary artery disease Diseases 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 8
- 230000036470 plasma concentration Effects 0.000 description 8
- 230000035484 reaction time Effects 0.000 description 8
- 239000011732 tocopherol Substances 0.000 description 8
- 229960001295 tocopherol Drugs 0.000 description 8
- 102000018616 Apolipoproteins B Human genes 0.000 description 7
- 108010027006 Apolipoproteins B Proteins 0.000 description 7
- 239000003963 antioxidant agent Substances 0.000 description 7
- 235000006708 antioxidants Nutrition 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 7
- 150000003904 phospholipids Chemical class 0.000 description 7
- 235000010384 tocopherol Nutrition 0.000 description 7
- 229930003799 tocopherol Natural products 0.000 description 7
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 7
- 208000024172 Cardiovascular disease Diseases 0.000 description 6
- 102000004895 Lipoproteins Human genes 0.000 description 6
- 108090001030 Lipoproteins Proteins 0.000 description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 6
- 229940125753 fibrate Drugs 0.000 description 6
- 238000002483 medication Methods 0.000 description 6
- 229960003512 nicotinic acid Drugs 0.000 description 6
- 235000001968 nicotinic acid Nutrition 0.000 description 6
- 239000011664 nicotinic acid Substances 0.000 description 6
- 208000032928 Dyslipidaemia Diseases 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 102000007513 Hemoglobin A Human genes 0.000 description 5
- 108010085682 Hemoglobin A Proteins 0.000 description 5
- 208000017170 Lipid metabolism disease Diseases 0.000 description 5
- 108010033266 Lipoprotein(a) Proteins 0.000 description 5
- 102000057248 Lipoprotein(a) Human genes 0.000 description 5
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 5
- 235000021068 Western diet Nutrition 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000002411 adverse Effects 0.000 description 5
- SNXPWYFWAZVIAU-UHFFFAOYSA-N arachidonic acid ethyl ester Natural products CCCCCC=CCC=CCC=CCC=CCCCC(=O)OCC SNXPWYFWAZVIAU-UHFFFAOYSA-N 0.000 description 5
- SNXPWYFWAZVIAU-GKFVBPDJSA-N ethyl arachidonate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OCC SNXPWYFWAZVIAU-GKFVBPDJSA-N 0.000 description 5
- GIODNRPAARSHAH-UHFFFAOYSA-N ethyl octadeca-2,4,6,8-tetraenoate Chemical compound CCCCCCCCCC=CC=CC=CC=CC(=O)OCC GIODNRPAARSHAH-UHFFFAOYSA-N 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 230000013632 homeostatic process Effects 0.000 description 5
- 208000006575 hypertriglyceridemia Diseases 0.000 description 5
- 230000000977 initiatory effect Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000007596 spatial working memory Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 4
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 4
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 4
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 4
- 208000035150 Hypercholesterolemia Diseases 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 235000021314 Palmitic acid Nutrition 0.000 description 4
- 102000015439 Phospholipases Human genes 0.000 description 4
- 108010064785 Phospholipases Proteins 0.000 description 4
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 4
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 4
- -1 VLDL-TG Proteins 0.000 description 4
- 230000036626 alertness Effects 0.000 description 4
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 4
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000002411 thermogravimetry Methods 0.000 description 4
- 238000012549 training Methods 0.000 description 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 3
- 102000016752 1-Alkyl-2-acetylglycerophosphocholine Esterase Human genes 0.000 description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 3
- 101710095342 Apolipoprotein B Proteins 0.000 description 3
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 3
- 108010024976 Asparaginase Proteins 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 206010028813 Nausea Diseases 0.000 description 3
- 239000005642 Oleic acid Substances 0.000 description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229940066279 eicosapentaenoate Drugs 0.000 description 3
- 235000021588 free fatty acids Nutrition 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 229940100601 interleukin-6 Drugs 0.000 description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 3
- 238000009533 lab test Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 206010027175 memory impairment Diseases 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 230000008693 nausea Effects 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 229940012843 omega-3 fatty acid Drugs 0.000 description 3
- 239000006014 omega-3 oil Substances 0.000 description 3
- 208000020016 psychiatric disease Diseases 0.000 description 3
- 238000012797 qualification Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 2
- HOBAELRKJCKHQD-UHFFFAOYSA-N (8Z,11Z,14Z)-8,11,14-eicosatrienoic acid Natural products CCCCCC=CCC=CCC=CCCCCCCC(O)=O HOBAELRKJCKHQD-UHFFFAOYSA-N 0.000 description 2
- 102000007592 Apolipoproteins Human genes 0.000 description 2
- 108010071619 Apolipoproteins Proteins 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-M Arachidonate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC([O-])=O YZXBAPSDXZZRGB-DOFZRALJSA-M 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 238000001061 Dunnett's test Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 2
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 2
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- AHANXAKGNAKFSK-PDBXOOCHSA-N all-cis-icosa-11,14,17-trienoic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCCCC(O)=O AHANXAKGNAKFSK-PDBXOOCHSA-N 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 229940114078 arachidonate Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000037998 chronic venous disease Diseases 0.000 description 2
- 230000003931 cognitive performance Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 238000009223 counseling Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 208000024732 dysthymic disease Diseases 0.000 description 2
- PRHHYVQTPBEDFE-UHFFFAOYSA-N eicosatrienoic acid Natural products CCCCCC=CCC=CCCCCC=CCCCC(O)=O PRHHYVQTPBEDFE-UHFFFAOYSA-N 0.000 description 2
- 230000001667 episodic effect Effects 0.000 description 2
- 230000001073 episodic memory Effects 0.000 description 2
- 235000004626 essential fatty acids Nutrition 0.000 description 2
- DTMGIJFHGGCSLO-FIAQIACWSA-N ethyl (4z,7z,10z,13z,16z,19z)-docosa-4,7,10,13,16,19-hexaenoate;ethyl (5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC.CCOC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC DTMGIJFHGGCSLO-FIAQIACWSA-N 0.000 description 2
- 235000021323 fish oil Nutrition 0.000 description 2
- 229960003765 fluvastatin Drugs 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000011545 laboratory measurement Methods 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 2
- 229960004844 lovastatin Drugs 0.000 description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 2
- 229940115970 lovaza Drugs 0.000 description 2
- 230000006996 mental state Effects 0.000 description 2
- 229950009116 mevastatin Drugs 0.000 description 2
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 description 2
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 229960002797 pitavastatin Drugs 0.000 description 2
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 2
- 229960002965 pravastatin Drugs 0.000 description 2
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 229940103121 simvastatin 80 mg Drugs 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000002562 urinalysis Methods 0.000 description 2
- 230000001755 vocal effect Effects 0.000 description 2
- MNVDOLYULIAMDA-AGRJPVHOSA-N (9z,12z,15z)-2-ethyloctadeca-9,12,15-trienoic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCC(CC)C(O)=O MNVDOLYULIAMDA-AGRJPVHOSA-N 0.000 description 1
- 125000006724 (C1-C5) alkyl ester group Chemical group 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- YMHOBZXQZVXHBM-UHFFFAOYSA-N 2,5-dimethoxy-4-bromophenethylamine Chemical compound COC1=CC(CCN)=C(OC)C=C1Br YMHOBZXQZVXHBM-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000017189 Gastrointestinal inflammatory disease Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000034991 Hiatal Hernia Diseases 0.000 description 1
- 206010020028 Hiatus hernia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- 206010023848 Laryngeal pain Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010030216 Oesophagitis Diseases 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 206010036018 Pollakiuria Diseases 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 206010060753 Type IV hyperlipidaemia Diseases 0.000 description 1
- QWDCYFDDFPWISL-UHFFFAOYSA-N UNPD207407 Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(=O)OC QWDCYFDDFPWISL-UHFFFAOYSA-N 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 241000545067 Venus Species 0.000 description 1
- 208000002223 abdominal aortic aneurysm Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 208000007474 aortic aneurysm Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- QWDCYFDDFPWISL-JEBPEJKESA-N cis-5,8,11,14,17-eicosapentaenoic acid methyl ester Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OC QWDCYFDDFPWISL-JEBPEJKESA-N 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000015961 delipidation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000011850 desserts Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 208000006881 esophagitis Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 235000019387 fatty acid methyl ester Nutrition 0.000 description 1
- 229960003580 felodipine Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003933 intellectual function Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 238000004848 nephelometry Methods 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940098695 palmitic acid Drugs 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 238000013105 post hoc analysis Methods 0.000 description 1
- 235000020991 processed meat Nutrition 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 235000020989 red meat Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 231100000402 unacceptable toxicity Toxicity 0.000 description 1
- 208000022934 urinary frequency Diseases 0.000 description 1
- 230000036318 urination frequency Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 108010017342 very high density lipoproteins Proteins 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261584013P | 2012-01-06 | 2012-01-06 | |
| US201261656347P | 2012-06-06 | 2012-06-06 | |
| US201261670408P | 2012-07-11 | 2012-07-11 | |
| PCT/US2013/020526 WO2013103958A1 (en) | 2012-01-06 | 2013-01-07 | Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2891473T3 true ES2891473T3 (es) | 2022-01-28 |
Family
ID=48745474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13733751T Active ES2891473T3 (es) | 2012-01-06 | 2013-01-07 | Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US9827219B2 (OSRAM) |
| EP (1) | EP2800469B1 (OSRAM) |
| JP (2) | JP6307442B2 (OSRAM) |
| AU (4) | AU2013207368A1 (OSRAM) |
| ES (1) | ES2891473T3 (OSRAM) |
| WO (1) | WO2013103958A1 (OSRAM) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3578177A1 (en) | 2008-09-02 | 2019-12-11 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same |
| CN102458109B (zh) | 2009-04-29 | 2015-02-11 | 阿马里纳制药公司 | 稳定的药物组合物和使用其的方法 |
| MX2011011517A (es) | 2009-04-29 | 2012-06-19 | Amarin Corp Plc | Composiciones farmaceuticas que comprenden epa y un agente cardiovascular y metodos para utilizar el mismo. |
| LT2443246T (lt) | 2009-06-15 | 2018-03-26 | Amarin Pharmaceuticals Ireland Limited | Kompozicijos ir būdai, skirti trigliceridų sumažinimui, nepakeliant ldl-c lygio subjekte, kartu taikant statino terapiją |
| US20110071176A1 (en) | 2009-09-23 | 2011-03-24 | Amarin Pharma, Inc. | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| AU2011336856A1 (en) | 2010-11-29 | 2013-07-04 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US20130131170A1 (en) | 2011-11-07 | 2013-05-23 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| WO2013103958A1 (en) | 2012-01-06 | 2013-07-11 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject |
| BR112014032905B1 (pt) | 2012-06-29 | 2022-02-22 | Amarin Pharmaceuticals Ireland Limited | Uso de éster etílico do ácido eicosapentaenóico para redução do risco de morte cardiovascular, revascularização coronária e/ou angina instável em um indivíduo em terapia com estatina |
| US20150265566A1 (en) | 2012-11-06 | 2015-09-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
| US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
| US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
| US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
| US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| WO2015066512A1 (en) * | 2013-10-31 | 2015-05-07 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
| US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| WO2018213663A1 (en) * | 2017-05-19 | 2018-11-22 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
| US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
| CN109125311A (zh) * | 2018-06-26 | 2019-01-04 | 东南大学 | 预防或治疗阿尔茨海默症的药物组合物及其应用 |
| MA51766A (fr) | 2018-09-24 | 2020-12-16 | Amarin Pharmaceuticals Ie Ltd | Procédés de réduction du risque d'événements cardiovasculaires chez un sujet |
| CN114980973A (zh) | 2019-11-12 | 2022-08-30 | 阿马里纳药物爱尔兰有限公司 | 降低心房纤颤和/或心房扑动受试者心血管事件风险的方法 |
| AU2022263358A1 (en) | 2021-04-21 | 2023-11-30 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
Family Cites Families (309)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU527784B2 (en) | 1978-05-26 | 1983-03-24 | Bang, Hans Olaf Dr. | Treatment of thromboembolic conditions withall-z)-5, 8, 11, 14, 17-eicosapentaenoic acid |
| US4377526A (en) | 1981-05-15 | 1983-03-22 | Nippon Suisan Kaisha, Ltd. | Method of purifying eicosapentaenoic acid and its esters |
| CA1239587A (en) | 1983-10-24 | 1988-07-26 | David Rubin | Combined fatty acid composition for lowering blood cholestrol and triglyceride levels |
| US4526902A (en) | 1983-10-24 | 1985-07-02 | Century Laboratories, Inc. | Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions |
| JPS6135356A (ja) | 1984-07-27 | 1986-02-19 | Nippon Oil & Fats Co Ltd | 血液脂質脂肪酸の分析方法 |
| EP0347509A1 (en) | 1988-06-21 | 1989-12-27 | Century Laboratories Inc. | A process of extraction and purification of polyunsaturated fatty acids from natural sources |
| US4920098A (en) | 1986-09-17 | 1990-04-24 | Baxter International Inc. | Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases |
| AU602376B2 (en) | 1986-12-26 | 1990-10-11 | Sagami Chemical Research Center | Process for production of eicosapentaenoic acid |
| JPS63185390A (ja) | 1987-01-27 | 1988-07-30 | Suntory Ltd | 藻類によるエイコサペンタエン酸の製造方法 |
| US5252333A (en) | 1987-04-27 | 1993-10-12 | Scotia Holdings Plc | Lithium salt-containing pharmaceutical compositions |
| US5198468A (en) | 1987-06-24 | 1993-03-30 | Efamol Holdings Plc | Essential fatty acid composition |
| US4843095A (en) | 1987-08-07 | 1989-06-27 | Century Laboratories, Inc. | Free fatty acids for treatment or propyhlaxis of rheumatoid arthritis arthritis |
| GB8819110D0 (en) | 1988-08-11 | 1988-09-14 | Norsk Hydro As | Antihypertensive drug & method for production |
| CA1338683C (en) | 1988-09-13 | 1996-10-29 | Efamol Holdings Plc | Fatty acid therapy and compositions |
| GB2223943A (en) | 1988-10-21 | 1990-04-25 | Tillotts Pharma Ag | Oral disage forms of omega-3 polyunsaturated acids |
| US4935243A (en) | 1988-12-19 | 1990-06-19 | Pharmacaps, Inc. | Chewable, edible soft gelatin capsule |
| JP2839276B2 (ja) | 1989-01-23 | 1998-12-16 | 日本分光工業株式会社 | 超臨界流体抽出・分離方法及び装置 |
| US5457130A (en) | 1989-03-20 | 1995-10-10 | Cancer Research Campaign Technology Limited | Eicosapentaenoic acid used to treat cachexia |
| GB8906369D0 (en) | 1989-03-20 | 1989-05-04 | Tisdale Michael J | Eicosapentaenoic acid |
| CA2043615C (en) | 1990-06-04 | 2001-08-14 | Kazuhiko Hata | Method of producing eicosapentaenoic acid or the ester derivative thereof |
| GB9012651D0 (en) | 1990-06-06 | 1990-07-25 | Efamol Holdings | Essential fatty acid treatment |
| JP3103588B2 (ja) | 1990-11-16 | 2000-10-30 | 持田製薬株式会社 | リポプロテイン（ａ）低下剤 |
| SE9101642D0 (sv) | 1991-05-30 | 1991-05-30 | Kabi Pharmacia Ab | Phospholipids |
| US5215630A (en) | 1991-06-04 | 1993-06-01 | Nippon Suisan Kaisha, Ltd. | Method of purifying eicosapentaenoic acid or the ester derivative thereof by fractional distillation |
| WO1993003450A1 (en) | 1991-07-30 | 1993-02-18 | North Carolina State University | Method and apparatus for measuring blood lipoprotein levels by nmr spectroscopy |
| DE4133694C2 (de) | 1991-10-11 | 1993-10-07 | Fresenius Ag | Verwendung einer Emulsion mit mehrfach ungesättigten Fettsären zur i.v.-Verabreichung zur Behandlung von Hauterkrankungen |
| JP3400466B2 (ja) | 1991-10-28 | 2003-04-28 | 日本水産株式会社 | 高純度エイコサペンタエン酸またはそのエステルの製造方法 |
| JPH0649479A (ja) | 1992-07-28 | 1994-02-22 | Maruha Corp | ω−３不飽和脂肪酸系化合物の安定化法 |
| GB9217780D0 (en) | 1992-08-21 | 1992-10-07 | Efamol Holdings | Fatty acid treatment |
| US5888541A (en) | 1992-08-21 | 1999-03-30 | Scotia Holdings Plc | Fatty acid treatment |
| JPH0692847A (ja) | 1992-09-11 | 1994-04-05 | Mochida Pharmaceut Co Ltd | 骨粗鬆症治療剤 |
| GB9300125D0 (en) | 1993-01-06 | 1993-03-03 | Scotia Holdings Plc | Compositions containing esters of unsaturated fatty acids |
| WO1994028891A1 (en) | 1993-06-04 | 1994-12-22 | Martek Biosciences Corporation | Method of treating coronary vascular disease using docosahexaenoic acid |
| GB9318611D0 (en) | 1993-09-08 | 1993-10-27 | Sandoz Nutrition Ltd | Improvements in or relating to organic compounds |
| JP3325995B2 (ja) | 1994-02-28 | 2002-09-17 | ミサワホーム株式会社 | パネル接合構造 |
| GB9403857D0 (en) | 1994-03-01 | 1994-04-20 | Scotia Holdings Plc | Fatty acid derivatives |
| GB9404483D0 (en) | 1994-03-08 | 1994-04-20 | Norsk Hydro As | Refining marine oil compositions |
| US5385929A (en) | 1994-05-04 | 1995-01-31 | Warner-Lambert Company | [(Hydroxyphenylamino) carbonyl] pyrroles |
| US5760081A (en) | 1994-05-10 | 1998-06-02 | The General Hospital Corporation | Omega 3 fatty acids in the prevention of ventricular fibrillation |
| JP3368100B2 (ja) | 1994-06-02 | 2003-01-20 | キヤノン株式会社 | 静電荷像現像用トナー |
| AU711482B2 (en) | 1994-06-28 | 1999-10-14 | Scotia Holdings Plc | Compositions for treatment of diabetic complications |
| IT1274734B (it) | 1994-08-25 | 1997-07-24 | Prospa Bv | Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti |
| JP2780154B2 (ja) | 1995-02-17 | 1998-07-30 | 株式会社ヤクルト本社 | ヨーグルト |
| MY118354A (en) | 1995-05-01 | 2004-10-30 | Scarista Ltd | 1,3-propane diol derivatives as bioactive compounds |
| GB9509764D0 (en) | 1995-05-15 | 1995-07-05 | Tillotts Pharma Ag | Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids |
| JPH0959206A (ja) | 1995-08-25 | 1997-03-04 | Nippon Oil & Fats Co Ltd | エイコサペンタエン酸およびエイコサペンタエン酸エステルの製造方法 |
| GB9519661D0 (en) | 1995-09-27 | 1995-11-29 | Scotia Holdings Plc | Fatty acid treatment |
| US5763496A (en) | 1995-11-27 | 1998-06-09 | The Research Foundation Of State University Of New York | Prevention of atherosclerosis using NADPH oxidase inhibitors |
| AU2738497A (en) | 1996-04-24 | 1997-11-12 | Brigham And Women's Hospital | Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder |
| US6077828A (en) | 1996-04-25 | 2000-06-20 | Abbott Laboratories | Method for the prevention and treatment of cachexia and anorexia |
| US6248398B1 (en) | 1996-05-22 | 2001-06-19 | Applied Materials, Inc. | Coater having a controllable pressurized process chamber for semiconductor processing |
| TW425285B (en) | 1996-06-10 | 2001-03-11 | Viva America Marketing Inc | Fish oil and garlic nutritive supplement |
| US5861399A (en) | 1996-07-17 | 1999-01-19 | Heart Care Partners | Methods and compositions for the rapid and enduring relief of inadequate myocardial function |
| US20020055539A1 (en) | 1996-10-02 | 2002-05-09 | Bockow Barry I. | Compositions and methods for treating cardiovascular conditions |
| DK0956013T3 (da) | 1996-10-11 | 2003-08-04 | Scarista Ltd | Farmaceutisk præparat indeholdende eicosapentaensyre og/eller stearidonsyre |
| DE69622722T2 (de) | 1996-11-20 | 2003-02-27 | N.V. Nutricia, Zoetermeer | Fette enthaltende Ernährungszusammensetzung zur Behandlung des Stoffwechselsyndroms |
| US20010006644A1 (en) | 1997-07-31 | 2001-07-05 | David J. Bova | Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night |
| KR100569319B1 (ko) | 1997-10-30 | 2006-04-07 | 모리시타 진탄 가부시키가이샤 | 불포화 지방산 또는 이들의 유도체를 내용물로 하는 캡슐제제 및 그의 제조방법 |
| WO1999026583A2 (en) | 1997-11-25 | 1999-06-03 | Warner-Lambert Company | Inhibtion of lipoprotein oxidation |
| ATE497384T1 (de) | 1997-12-10 | 2011-02-15 | Cyclosporine Therapeutics Ltd | Omega-3 fettsäure enthaltende pharmazeutische zusammensetzungen |
| NZ500703A (en) | 1998-11-04 | 2001-06-29 | F | Preparation of food-grade marine edible oils by treatment with silica, vacuum steam deodorisation and addition of a herb extract |
| US20020055529A1 (en) | 1998-12-02 | 2002-05-09 | Bisgaier Charles Larry | Method for treating alzheimer's disease |
| GB9901809D0 (en) | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
| CA2260397A1 (en) | 1999-01-29 | 2000-07-29 | Atlantis Marine Inc. | Method of converting rendered triglyceride oil from marine sources into bland, stable food oil |
| US20030104048A1 (en) | 1999-02-26 | 2003-06-05 | Lipocine, Inc. | Pharmaceutical dosage forms for highly hydrophilic materials |
| US6193999B1 (en) | 1999-03-01 | 2001-02-27 | Banner Pharmacaps, Inc. | Gum acacia substituted soft gelatin capsules |
| DE60005152T2 (de) | 1999-03-03 | 2004-07-08 | Eurovita A/S | Arzneimittel, nahrungszusätze und kosmetische zubereitung enthaltend eine fettsäure und ingwer |
| ES2286999T5 (es) | 1999-03-04 | 2016-11-17 | Suntory Holdings Limited | Utilización de un material que contiene ácido docosapentaenoico |
| US20020054871A1 (en) | 1999-04-12 | 2002-05-09 | Yadong Huang | Methods and compositions for use in the treatment of hyperlipidemia |
| US7112609B2 (en) | 1999-06-01 | 2006-09-26 | Drugtech Corporation | Nutritional supplements |
| US6207699B1 (en) | 1999-06-18 | 2001-03-27 | Richard Brian Rothman | Pharmaceutical combinations for treating obesity and food craving |
| CA2311974A1 (en) | 1999-06-28 | 2000-12-28 | Nisshin Flour Milling Co., Ltd. | Processes of selectively separating and purifying eicosapentaenoic and docosahexaenoic acids or their esters |
| GB9916536D0 (en) | 1999-07-14 | 1999-09-15 | Scarista Limited | Nutritional or pharmaceutical compositions |
| ATE394941T1 (de) | 1999-07-28 | 2008-05-15 | Swiss Caps Rechte & Lizenzen | Präparat zur verwendung als medikament und/oder nahrungsmittelergänzung |
| EP1211955A1 (en) | 1999-08-30 | 2002-06-12 | Ocean Nutrition Canada Ltd. | A nutritional supplement for lowering serum triglyceride and cholesterol levels |
| JP4170542B2 (ja) | 1999-11-18 | 2008-10-22 | 日油株式会社 | 高度不飽和脂肪酸誘導体の製造方法及び高純度エイコサペンタエン酸誘導体 |
| EP1125914A1 (en) | 2000-02-14 | 2001-08-22 | Nisshin Flour Milling Co., Ltd. | Process for separating and purifying eicosapentaenoic acid or its ester |
| ES2246769T3 (es) | 2000-05-22 | 2006-03-01 | Pro Aparts - Investimentos E Consultoria Lda | Composicion de acidos grasos que contiene al menos 80% en peso de epa y dha o sus derivados y su uso farmaceutico. |
| US6620821B2 (en) | 2000-06-15 | 2003-09-16 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
| GB0016045D0 (en) | 2000-06-29 | 2000-08-23 | Laxdale Limited | Therapeutic combinations of fatty acids |
| GB0016452D0 (en) | 2000-07-04 | 2000-08-23 | Kilgowan Limited | Vitamin K and essential fatty acids |
| JP4391673B2 (ja) | 2000-08-08 | 2009-12-24 | 花王株式会社 | 油脂組成物 |
| CA2419406A1 (en) | 2000-08-15 | 2002-02-21 | Pfizer Products Inc. | Pharmaceutical combinations of torcetrapib and atorvastatin or hydroxy derivatives for the treatment of atherosclerosis, angina and low hdl levels |
| GB0101198D0 (en) | 2001-01-17 | 2001-02-28 | Scherer Technologies Inc R P | Ingestible compositions containing an odoriferous oil |
| ITMI20010129A1 (it) | 2001-01-25 | 2002-07-25 | Pharmacia & Upjohn Spa | Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco |
| GB0111282D0 (en) | 2001-05-09 | 2001-06-27 | Laxdale Ltd | Potentiation of therapeutic effects of fatty acids |
| MXPA03010888A (es) | 2001-05-30 | 2004-02-27 | Laxdale Ltd | Coenzimas q y acido eicosapentaenoico (epa). |
| US20120214771A1 (en) | 2001-07-27 | 2012-08-23 | Fontini Sampalis | Compositions for treatment of cardiometabolic disorders |
| ITMI20012384A1 (it) | 2001-11-12 | 2003-05-12 | Quatex Nv | Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori |
| WO2003043570A2 (en) * | 2001-11-15 | 2003-05-30 | Galileo Laboratories, Inc. | Formulations and methods for treatment or amelioration of inflammatory conditions |
| ITMI20020269A1 (it) | 2002-02-12 | 2003-08-12 | Victorix Assets Ltd | Uso di steri etilici di acidi poliinsaturi omega-3 in pazienti con insufficienza cardiaca |
| JP2003306690A (ja) | 2002-02-18 | 2003-10-31 | Nooburu:Kk | 多価不飽和脂肪酸含有油脂組成物 |
| US20030166614A1 (en) | 2002-03-01 | 2003-09-04 | Harrison Stanley F. | Method for reducing cholesterol and triglycerides |
| EP1501493B1 (en) | 2002-05-03 | 2009-10-07 | Pronova BioPharma Norge AS | Use of epa and dha in secondary prevention of strokes |
| WO2003103582A2 (en) | 2002-06-05 | 2003-12-18 | Ivax Corporation | Reduction of gelatin cross-linking |
| US7157235B2 (en) | 2002-06-17 | 2007-01-02 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
| US20040001874A1 (en) | 2002-06-24 | 2004-01-01 | Vital Living, Inc. | Safe and effective nutritional supplement formulations and associated regimens adapted to prevent and/or treat targeted diseases or medical or health conditions, and related methods |
| JP2005532394A (ja) * | 2002-07-02 | 2005-10-27 | ガリレオ ファーマシューティカルズ， インコーポレイティド | 雌性被験体における炎症性症状および／またはバイオマーカーの低減のための組成物および方法 |
| US20060211761A1 (en) | 2002-07-08 | 2006-09-21 | Yatendra Kumar | Hmg-coa-reductase inhibitors |
| US20080200453A1 (en) | 2002-07-29 | 2008-08-21 | Cincotta Anthony H | Methods of treating metabolic syndrome using dopamine receptor agonists |
| US7314643B2 (en) | 2002-08-20 | 2008-01-01 | Nikken Chemicals Co., Ltd. | Soft capsule preparation |
| US7511131B2 (en) | 2002-11-13 | 2009-03-31 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
| KR20110053281A (ko) | 2002-11-22 | 2011-05-19 | 니폰스이산가부시키가이샤 | 산화 안정성이 향상된 이중결합을 가진 유기물을 함유하는 조성물 |
| US8017651B2 (en) | 2002-11-22 | 2011-09-13 | Bionexus, Ltd. | Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia |
| GB0228079D0 (en) | 2002-12-02 | 2003-01-08 | Laxdale Ltd | Huntington's Disease |
| US8124582B2 (en) * | 2002-12-06 | 2012-02-28 | Fibrogen, Inc. | Treatment of diabetes |
| GB0301701D0 (en) | 2003-01-24 | 2003-02-26 | Ensay Ltd | Psoriasis and Eicosapentaenoic acid |
| WO2004068970A2 (en) | 2003-01-31 | 2004-08-19 | The Procter & Gamble Company | Means for improving the appearance of mammalian keratinous tissue |
| WO2004069238A1 (ja) | 2003-02-07 | 2004-08-19 | Mochida Pharmaceutical Co., Ltd. | くも膜下出血の予後改善剤 |
| US20060088502A1 (en) | 2003-02-21 | 2006-04-27 | Michio Sata | Drug for reducing side effects in ribavirin interferon combination therapy |
| CA2515328A1 (en) | 2003-03-05 | 2004-09-16 | Solvay Pharmaceuticals Gmbh | Use of omega-3-fatty acids in the treatment of diabetic patients |
| PL377614A1 (pl) | 2003-03-18 | 2006-02-06 | Novartis Ag | Kompozycje zawierające kwasy tłuszczowe i aminokwasy |
| US7598227B2 (en) | 2003-04-16 | 2009-10-06 | Isis Pharmaceuticals Inc. | Modulation of apolipoprotein C-III expression |
| US6846942B2 (en) | 2003-05-20 | 2005-01-25 | David Rubin | Method for preparing pure EPA and pure DHA |
| US7205329B2 (en) | 2003-05-30 | 2007-04-17 | Microbia, Inc. | Modulators of CRTH2 activity |
| JP4870430B2 (ja) | 2003-06-20 | 2012-02-08 | 持田製薬株式会社 | 下肢静脈瘤予防・治療用組成物 |
| WO2005020785A2 (en) | 2003-07-15 | 2005-03-10 | The Regents Of The University Of California | Discovery of the microorganism that causes the human autoimmune disease, primary biliary cirrhosis |
| AU2003249492A1 (en) | 2003-07-24 | 2005-02-14 | Eswaran Krishnan Iyer | Oral compositions for treatment of diseases |
| US20050132441A1 (en) | 2003-11-12 | 2005-06-16 | Damude Howard G. | Delta15 desaturases suitable for altering levels of polyunsaturated fatty acids in oilseed plants and oleaginous yeast |
| ITMI20032247A1 (it) | 2003-11-19 | 2005-05-20 | Tiberio Bruzzese | Interazione di derivati polari di composti insaturi con substrati inorganici |
| SE0303513D0 (sv) | 2003-12-19 | 2003-12-19 | Pronova Biocare As | Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof |
| WO2005063231A2 (en) | 2003-12-31 | 2005-07-14 | Igennus Limited | Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or esther thereof |
| IL159729A0 (en) | 2004-01-06 | 2004-06-20 | Doron I Friedman | Non-aqueous composition for oral delivery of insoluble bioactive agents |
| GB0403247D0 (en) | 2004-02-13 | 2004-03-17 | Tillotts Pharma Ag | A pharmaceutical composition |
| US7022713B2 (en) | 2004-02-19 | 2006-04-04 | Kowa Co., Ltd. | Hyperlipemia therapeutic agent |
| EP1591114A1 (en) | 2004-03-12 | 2005-11-02 | Fournier Laboratories Ireland Limited | Use of metformin and orlistat for the treatment or prevention of obesity |
| US20050215640A1 (en) | 2004-03-26 | 2005-09-29 | Baxter Jeffrey H | HMB compositions and uses thereof |
| US7923043B2 (en) | 2004-03-30 | 2011-04-12 | Theta Biomedical Consulting & Development Co., Inc. | Method for protecting humans against superficial vasodilator flush syndrome |
| US20050244367A1 (en) | 2004-05-03 | 2005-11-03 | Ilypsa, Inc. | Phospholipase inhibitors localized in the gastrointestinal lumen |
| WO2005114190A2 (en) | 2004-05-19 | 2005-12-01 | Ppd Biomarker Discovery Sciences, Llc | Methods of identifying biomarkers |
| TW200613009A (en) | 2004-06-11 | 2006-05-01 | Ono Pharmaceutical Co | Capsule having chewing stability |
| GB0413729D0 (en) | 2004-06-18 | 2004-07-21 | Tillotts Pharma Ag | A pharmaceutical composition and its use |
| GB0413730D0 (en) | 2004-06-18 | 2004-07-21 | Tillotts Pharma Ag | A pharmaceutical composition and its use |
| JP2007284350A (ja) | 2004-07-27 | 2007-11-01 | Takeda Chem Ind Ltd | 糖尿病治療剤 |
| ITRM20040395A1 (it) | 2004-08-03 | 2004-11-03 | Sigma Tau Ind Farmaceuti | Composizione comprendente statine e acidi grassi omega 3. |
| AU2005271413A1 (en) | 2004-08-06 | 2006-02-16 | Transform Pharmaceuticals, Inc. | Novel statin pharmaceutical compositions and related methods of treatment |
| US20090042979A1 (en) | 2004-08-06 | 2009-02-12 | Transform Pharmaceuticals Inc. | Novel Statin Pharmaceutical Compositions and Related Methods of Treatment |
| WO2006017627A2 (en) | 2004-08-06 | 2006-02-16 | Barry Sears | Dietary compositions comprising docosahexaenoic acid and eicosapentaenoic acid and use thereof for treating insulin resistance |
| CA2577345C (en) | 2004-08-18 | 2013-02-19 | Hiroki Ueshima | Jelly composition |
| US20060051418A1 (en) | 2004-08-25 | 2006-03-09 | Essentialis, Inc. | Pharmaceutical formulations of potassium ATP channel openers and uses thereof |
| CN1759834B (zh) | 2004-09-17 | 2010-06-23 | 中国医学科学院医药生物技术研究所 | 黄连素或其与辛伐他汀联合在制备用于预防或治疗与血脂有关疾病或症状的产品中用途 |
| DE602005010899D1 (de) | 2004-09-27 | 2008-12-18 | Sigmoid Pharma Ltd | Mikrokapseln mit einem methylxanthin und einem kortikosteroid |
| JP5491697B2 (ja) * | 2004-10-15 | 2014-05-14 | フォトンズ コーポレイション リミテッド | 高レベルオメガ−３および低レベル飽和脂肪酸を含む組成物 |
| FR2878747B1 (fr) | 2004-12-03 | 2007-03-30 | Pierre Fabre Medicament Sa | Utilisation d'acide(s) gras omega-3 pour le traitement de l'hypercholesterolemie causee par un traitement anti-retroviral chez les patients infectes par le vih |
| KR101356335B1 (ko) | 2004-12-06 | 2014-02-06 | 릴라이언트 파마슈티컬스 인코퍼레이티드 | 지질 치료를 위한 오메가-3 지방산 및 이상지질혈증 제제 |
| CN101098690A (zh) | 2004-12-06 | 2008-01-02 | 瑞莱恩特医药品有限公司 | 用于血脂治疗的ω-3脂肪酸和脂血异常剂 |
| US20090239927A1 (en) | 2004-12-06 | 2009-09-24 | George Bobotas | Statin and Omega-3 Fatty Acids For Lipid Therapy |
| US20070191467A1 (en) | 2004-12-06 | 2007-08-16 | Reliant Pharmaceutical, Inc. | Statin and omega-3 fatty acids for lipid therapy |
| US20060135610A1 (en) | 2004-12-22 | 2006-06-22 | Bortz Jonathan D | Cardiovascular compositions |
| GB2421909A (en) | 2004-12-23 | 2006-07-12 | Laxdale Ltd | Pharmaceutical compositions comprising EPA and methods of use |
| US20080200707A1 (en) | 2005-01-04 | 2008-08-21 | Mochida-Pharmaceuticals Pharmaceutical Co., Ltd. | Lipotoxicity Relieving Agent |
| CA2593768C (en) | 2005-01-04 | 2014-02-18 | Mochida Pharmaceutical Co., Ltd. | Use of .omega.3 unsaturated fatty acids for relieving lipotoxicity |
| ATE528005T1 (de) | 2005-01-10 | 2011-10-15 | Cortendo Ab Publ | 2s,4r ketoconazol zur behandlung von diabetes, metabolischem syndrom und anderen erkrankungen |
| US20060172012A1 (en) | 2005-01-28 | 2006-08-03 | Finley John W | Anti-inflammatory supplement compositions and regimens to reduce cardiovascular disease risks |
| US20060189682A1 (en) | 2005-02-02 | 2006-08-24 | Payne Joseph E | Water soluble prodrugs of COX-2 inhibitors |
| US20080139604A1 (en) | 2005-02-17 | 2008-06-12 | Shaun Fitzpatrick | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions |
| US20100254951A1 (en) | 2005-02-22 | 2010-10-07 | Mochida Pharmaceutical Co., Ltd. | Nerve Regeneration Promoting Agent |
| US20060211763A1 (en) | 2005-03-08 | 2006-09-21 | Abdel Fawzy | Treatment with Statin and Omega-3 Fatty Acids and a Combination Product Thereof |
| EP1790339B1 (en) | 2005-07-08 | 2014-06-04 | Mochida Pharmaceutical Co., Ltd. | Composition for prevention of occurrence of cardiovascular event |
| MX2008000915A (es) | 2005-07-18 | 2008-04-04 | Reliant Pharmaceuticals Inc | Tratamiento con inhibidores de absorcion de colesterol basados en azetidinona y acidos grasos omega-3 y un producto de combinacion de los mismos. |
| RU2290185C1 (ru) | 2005-07-26 | 2006-12-27 | Дмитрий Николаевич Мясников | Композиция для нормализации липидного обмена и снижения массы тела и способ её получения |
| CA2616806A1 (en) | 2005-07-28 | 2007-02-08 | Reliant Pharmaceuticals, Inc. | Treatment with dihydropyridine calcium channel blockers and omega-3 fatty acids and a combination product thereof |
| ITMI20051560A1 (it) | 2005-08-10 | 2007-02-11 | Tiberio Bruzzese | Composizione di acidi grassi n-3 con elevata concentrazione di epa e-o dha e contenente acidi grassi n-6 |
| US7405302B2 (en) | 2005-10-11 | 2008-07-29 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (FLAP) inhibitors |
| US20090227602A1 (en) | 2005-10-28 | 2009-09-10 | John Griffin | Compositions and treatments for inhibiting kinase and/or hmg-coa reductase |
| US20070105793A1 (en) | 2005-11-04 | 2007-05-10 | Curt Hendrix | Compositions and methods using nicotinic acid for treatment of hypercholesterolemia, hyperlipidemia nd cardiovascular disease |
| US20070104779A1 (en) | 2005-11-07 | 2007-05-10 | Rongen Roelof M | Treatment with omega-3 fatty acids and products thereof |
| BRPI0618455A2 (pt) | 2005-11-11 | 2011-08-30 | Mochida Pharm Co Ltd | composição de geléia |
| WO2007058523A1 (en) | 2005-11-17 | 2007-05-24 | N.V. Nutricia | Composition with docosapentaenoic acid |
| BRPI0520669A2 (pt) | 2005-11-21 | 2009-06-02 | Teva Pharma | dosagem farmacêutica que reduz o efeito do alimento encontrado para administração de atorvastatina |
| CA2634139C (en) | 2005-12-20 | 2015-06-23 | Cenestra, Llc. | Omega 3 fatty acid formulations |
| PL1800675T4 (pl) | 2005-12-23 | 2012-02-29 | Nutricia Nv | Kompozycja zawierająca wielonienasycone kwasy tłuszczowe, białka, mangan, i/lub molibden oraz nukleozydy/nukleotydy do leczenia otępienia |
| US20070265340A1 (en) | 2006-01-05 | 2007-11-15 | Shalwitz Robert A | Treatment of fatty liver |
| EP1905424A3 (en) | 2006-02-02 | 2008-04-30 | Ranbaxy Laboratories Limited | Process for the preparation of a pharmaceutical composition comprising stabilized statin particles |
| CN103751781A (zh) | 2006-02-07 | 2014-04-30 | 持田制药株式会社 | 预防中风复发的组合物 |
| CN101395170A (zh) | 2006-02-14 | 2009-03-25 | 英特塞普特药品公司 | 用于预防或治疗fxr介导的疾病或状态的作为fxr配体的胆汁酸衍生物 |
| US8784886B2 (en) | 2006-03-09 | 2014-07-22 | GlaxoSmithKline, LLC | Coating capsules with active pharmaceutical ingredients |
| WO2007128801A1 (en) | 2006-05-08 | 2007-11-15 | Novartis Ag | Combination of organic compounds |
| EP2022495B1 (en) | 2006-05-31 | 2014-07-23 | Mochida Pharmaceutical Co., Ltd. | Composition for preventing the occurrence of cardiovascular event in multiple risk patient |
| NZ573719A (en) | 2006-07-05 | 2011-08-26 | Photonz Corp Ltd | Production of ultrapure eicosapentaenoic acid and polar lipids from largely heterotrophic culture of nitzschia laevis |
| US20090304784A1 (en) | 2006-07-28 | 2009-12-10 | V. Mane Fils | Seamless capsules containing high amounts of polyunsaturated fatty acids and a flavouring component |
| US20080085911A1 (en) | 2006-10-10 | 2008-04-10 | Reliant Pharmaceuticals, Inc. | Statin and omega-3 fatty acids for reduction of apo-b levels |
| CN101553221A (zh) | 2006-10-10 | 2009-10-07 | 瑞莱恩特医药品有限公司 | 用于降低APO-B水平的抑制素和ω-3脂肪酸 |
| WO2008088415A1 (en) | 2006-10-18 | 2008-07-24 | Reliant Pharmaceuticals, Inc. | Omega-3 fatty acids for reduction of lp-pla2 levels |
| US20080125490A1 (en) | 2006-11-03 | 2008-05-29 | My Svensson | Treatment and prevention of cardiovascular disease in patients with chronic kidney disease by administering Omega-3 Fatty Acids |
| US20080306154A1 (en) | 2006-11-03 | 2008-12-11 | My Svensson | Treatment and prevention of major adverse cardiovascular events or major coronary evens by administering Omega-3 fatty acids |
| EP2119443B1 (en) | 2007-01-17 | 2014-08-20 | Mochida Pharmaceutical Co., Ltd. | Composition for prevention or treatment of disease associated with thrombus or embolus |
| WO2008091338A1 (en) | 2007-01-23 | 2008-07-31 | Reddy Us Therapeutics, Inc. | Methods and compositions for the treatment of insulin resistance, diabetes, and diabetes-associated dyslipidemia |
| US20080185198A1 (en) | 2007-02-02 | 2008-08-07 | Steven Mark Jones | Next generation hybrid III parallel/series hybrid system |
| DK2121576T3 (en) | 2007-02-15 | 2016-02-15 | Ct De Rech Sur Les Biotechnologies Marine | Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof |
| CA2677036A1 (en) | 2007-03-06 | 2008-09-12 | Bioriginal Food & Science Corp. | Soft gelatin capsule shells containing oil soluble flavoring and methods of making the same |
| WO2008115529A1 (en) | 2007-03-20 | 2008-09-25 | Reliant Pharmaceuticals, Inc. | Compositions comprising omega-3 fatty acids and cetp inhibitors |
| WO2008145170A1 (de) | 2007-05-31 | 2008-12-04 | Siemens Aktiengesellschaft | Verfahren zum konfigurieren einer automatisierungsanlage |
| US20080299187A1 (en) | 2007-06-01 | 2008-12-04 | Joar Opheim | Substances for Reducing Occurence of Major Cardiac Events in Humans |
| KR20100039362A (ko) | 2007-06-29 | 2010-04-15 | 다케다 야쿠힌 고교 가부시키가이샤 | 심리스 캡슐 |
| EP2205231A1 (en) | 2007-10-01 | 2010-07-14 | NeuroSearch A/S | Pharmaceutical compositions of 5-hydr0xytrypt0phan and serotonin-enhancing compound |
| US8361534B2 (en) | 2007-12-20 | 2013-01-29 | Abbott Laboratories | Stable nutritional powder |
| BRPI0820584A2 (pt) | 2007-12-20 | 2015-07-14 | Abbott Lab | Pó nutricional estável |
| UA102477C2 (en) | 2008-01-10 | 2013-07-10 | Такеда Фармасьютикал Компани Лимитед | Capsule composition |
| US20090182049A1 (en) | 2008-01-16 | 2009-07-16 | Joar Arild Opheim | Pharmaceutical Composition and Method for Treating Hypertriglyceridemia and Hypercholesterolemia in Humans |
| MX2010012482A (es) | 2008-05-15 | 2010-12-01 | Pronova Biopharma Norge As | Proceso para aceite de kril. |
| CA2724983A1 (en) | 2008-05-20 | 2009-11-26 | Mochida Pharmaceutical Co., Ltd. | Composition for preventing cardiovascular event in high-risk patient |
| JPWO2009151125A1 (ja) | 2008-06-13 | 2011-11-17 | 持田製薬株式会社 | 肝障害の診断及び治療 |
| JPWO2009151116A1 (ja) | 2008-06-13 | 2011-11-17 | 持田製薬株式会社 | 非アルコール性脂肪肝炎の予防／改善・治療薬 |
| JPWO2009154230A1 (ja) | 2008-06-17 | 2011-12-01 | 持田製薬株式会社 | 非アルコール性脂肪肝炎の予防／改善・治療薬 |
| KR20110039249A (ko) | 2008-07-07 | 2011-04-15 | 모치다 세이야쿠 가부시키가이샤 | 지질 이상증의 개선 또는 치료약 |
| EP3578177A1 (en) * | 2008-09-02 | 2019-12-11 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same |
| JPWO2010038796A1 (ja) | 2008-09-30 | 2012-03-01 | 持田製薬株式会社 | Ｃ型肝炎治療剤 |
| US20100130608A1 (en) | 2008-10-01 | 2010-05-27 | Martek Biosciences Corporation | Compositions and methods for reducing triglyceride levels |
| US20120035105A1 (en) | 2009-01-09 | 2012-02-09 | Sdg, Inc. | Insulin Therapies for the Treatment of Diabetes, Diabetes Related Ailments, and/or Diseases or Conditions Other Than Diabetes or Diabetes Related Ailments |
| WO2010083615A1 (en) | 2009-01-26 | 2010-07-29 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing apolipoprotein c-iii expression |
| ES2769926T3 (es) | 2009-02-10 | 2020-06-29 | Amarin Pharmaceuticals Ie Ltd | Ester etílico del ácido eicosapentaenoico para tratar la hipertrigliceridemia |
| US8241672B2 (en) | 2009-03-11 | 2012-08-14 | Stable Solutions Llc | Omega-3 enriched fish oil-in-water parenteral nutrition emulsions |
| WO2010117951A1 (en) | 2009-04-06 | 2010-10-14 | The Regents Of The University Of California | Inhibitors of soluble epoxide hydrolase to inhibit or prevent niacin-induced flushing |
| CN102458109B (zh) | 2009-04-29 | 2015-02-11 | 阿马里纳制药公司 | 稳定的药物组合物和使用其的方法 |
| MX2011011517A (es) | 2009-04-29 | 2012-06-19 | Amarin Corp Plc | Composiciones farmaceuticas que comprenden epa y un agente cardiovascular y metodos para utilizar el mismo. |
| CA3059911C (en) | 2009-05-22 | 2022-01-11 | Mochida Pharmaceutical Co., Ltd. | Self-emulsifying composition of .omega.3 fatty acid |
| LT2443246T (lt) | 2009-06-15 | 2018-03-26 | Amarin Pharmaceuticals Ireland Limited | Kompozicijos ir būdai, skirti trigliceridų sumažinimui, nepakeliant ldl-c lygio subjekte, kartu taikant statino terapiją |
| RU2402326C1 (ru) | 2009-06-22 | 2010-10-27 | Учреждение Российской академии медицинских наук Дальневосточный научный центр физиологии и патологии дыхания Сибирского отделения Российской академии медицинских наук (ДНЦ ФПД СО РАМН) | Способ коррекции инсулинорезистентности при метаболическом синдроме |
| US8557275B2 (en) | 2009-07-23 | 2013-10-15 | U.S. Nutraceuticals, LLC | Composition and method to alleviate joint pain using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA |
| SG178948A1 (en) | 2009-09-01 | 2012-04-27 | Catabasis Pharmaceuticals Inc | Fatty acid niacin conjugates and their uses |
| US20110071176A1 (en) | 2009-09-23 | 2011-03-24 | Amarin Pharma, Inc. | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same |
| JP5951489B2 (ja) | 2009-10-16 | 2016-07-13 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | 組成物 |
| JP5758298B2 (ja) | 2009-10-16 | 2015-08-05 | 持田製薬株式会社 | 非アルコール性脂肪肝炎関連マーカー |
| EP2521447B1 (en) | 2010-01-08 | 2017-06-14 | Catabasis Pharmaceuticals, Inc. | Fatty acid fumarate derivatives and their uses |
| WO2011087981A2 (en) | 2010-01-15 | 2011-07-21 | E. I. Du Pont De Nemours And Company | Clinical benefits of eicosapentaenoic acid in humans |
| US20110218243A1 (en) | 2010-03-04 | 2011-09-08 | Amarin Pharma, Inc. | Compositions and methods for treating and/or preventing cardiovascular disease |
| US8846321B2 (en) | 2010-03-12 | 2014-09-30 | President And Fellows Of Harvard College | Association of levels of HDL-cholesterol apolipoprotein CIII with the risk of coronary heart disease and cardiovascular events |
| US8663704B2 (en) | 2010-04-30 | 2014-03-04 | U.S. Nutraceuticals, LLC | Composition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (LDL) per-oxidation in humans |
| GB2480146A (en) | 2010-05-05 | 2011-11-09 | St Giles Foods Ltd | Fruit or vegetable based edible composition comprising nutritional supplement |
| CA2803558C (en) | 2010-06-30 | 2018-05-29 | Mochida Pharmaceutical Co., Ltd. | .omega.3 fatty acid compound preparation |
| AR082930A1 (es) | 2010-09-08 | 2013-01-16 | Pronova Biopharma Norge As | Composiciones que comprenden una mezcla oleosa de acidos grasos, un tensioactivo y una estatina |
| US20130260403A1 (en) * | 2010-10-20 | 2013-10-03 | GlycoMark Inc. | Identification of pre-diabetes using a combination of mean glucose and 1,5-anhydroglucitol markers |
| WO2012063820A1 (ja) | 2010-11-09 | 2012-05-18 | 持田製薬株式会社 | 血糖値上昇抑制剤 |
| AU2011336856A1 (en) | 2010-11-29 | 2013-07-04 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| KR101310710B1 (ko) | 2011-03-23 | 2013-09-27 | 한미약품 주식회사 | 오메가-3 지방산 에스테르 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 경구용 복합 조성물 |
| US20120264824A1 (en) | 2011-04-15 | 2012-10-18 | Mochida Pharmaceutical Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
| KR20190062511A (ko) | 2011-04-27 | 2019-06-05 | 아이오니스 파마수티컬즈, 인코포레이티드 | 아포지방단백질 ｃｉｉｉ （ａｐｏｃｉｉｉ） 발현의 조정 |
| WO2013040507A1 (en) | 2011-09-15 | 2013-03-21 | Omthera Pharmaceuticals, Inc. | Methods and compositions for treating, reversing, inhibiting or preventing resistance to antiplatelet therapy |
| US20130131170A1 (en) | 2011-11-07 | 2013-05-23 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| US20140323709A1 (en) | 2011-12-12 | 2014-10-30 | National Cerebral And Cardiovascular Center | Oligonucleotide and therapeutic agent for hyperlipidemia containing same as active ingredient |
| WO2013103958A1 (en) | 2012-01-06 | 2013-07-11 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject |
| AU2013240427B2 (en) | 2012-03-30 | 2017-08-03 | Sancilio & Company, Inc. | Omega-3 fatty acid ester compositions |
| AR095182A1 (es) | 2012-05-07 | 2015-09-30 | Omthera Pharmaceuticals Inc | Composiciones de estatinas y ácidos grasos omega-3 |
| EP2851069B1 (en) | 2012-05-15 | 2019-08-28 | Mochida Pharmaceutical Co., Ltd. | Cardiovascular disease primary prevention agent for patients having high blood levels of high-sensitivity c-reactive protein |
| BR112014029757A2 (pt) | 2012-05-30 | 2017-06-27 | Clariant Finance Bvi Ltd | composição contendo tensoativos do tipo aminoácido, betaínas e n-metil-n-acilglucaminas e tendo qualidade de espuma melhorada e maior viscosidade |
| US20130324607A1 (en) | 2012-06-05 | 2013-12-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypercholesterolemia |
| US20140080850A1 (en) | 2012-06-05 | 2014-03-20 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising an omega-3 fatty acid and a hydroxy-derivative of a statin and methods of using same |
| EP2861227A4 (en) | 2012-06-17 | 2016-01-27 | Matinas Biopharma Inc | OMEGA-3 PENTAIC ACID COMPOSITIONS AND METHODS OF USE |
| EP3682875A3 (en) | 2012-06-29 | 2020-10-21 | Amarin Pharmaceuticals Ireland Limited | Methods of treating pediatric metabolic syndrome |
| US20140005265A1 (en) | 2012-06-29 | 2014-01-02 | Amarin Pharmaceuticals Ireland Limited | Methods for treating hypertriglyceridemia |
| BR112014032905B1 (pt) | 2012-06-29 | 2022-02-22 | Amarin Pharmaceuticals Ireland Limited | Uso de éster etílico do ácido eicosapentaenóico para redução do risco de morte cardiovascular, revascularização coronária e/ou angina instável em um indivíduo em terapia com estatina |
| US20140004183A1 (en) | 2012-06-29 | 2014-01-02 | Amarin Pharmaceuticals Ireland Limited | Methods for treating cardiovascular disease in statin-tolerant subjects |
| US20150157593A1 (en) | 2012-06-29 | 2015-06-11 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing ldl-p |
| JP6196225B2 (ja) | 2012-09-28 | 2017-09-13 | 持田製薬株式会社 | 糖尿病新規発症低減用組成物 |
| US9486433B2 (en) | 2012-10-12 | 2016-11-08 | Mochida Pharmaceuticals Co. Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
| EP2719382A1 (en) | 2012-10-12 | 2014-04-16 | Mochida Pharmaceutical Co., Ltd. | Ethyl Eicosapentanoate and Pharmaceutical Compositions Comprising Ethyl Eicosapentanoate as an Active Ingredient for Use in the Treatment of Non-Alcoholic Steatohepatitis |
| US20150265566A1 (en) | 2012-11-06 | 2015-09-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| US20140213648A1 (en) | 2012-12-31 | 2014-07-31 | Amarin Pharmaceuticals Ireland Limited | Methods of increasing epa blood levels |
| US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
| US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| US20140221358A1 (en) | 2013-02-06 | 2014-08-07 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and diazoxide and methods of use thereof |
| US20140221452A1 (en) | 2013-02-06 | 2014-08-07 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and 5-htp and methods of use thereof |
| US20140221676A1 (en) | 2013-02-06 | 2014-08-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating and/or preventing cardiovascular disease |
| US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
| US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
| US20140242216A1 (en) | 2013-02-24 | 2014-08-28 | Mead Johnson Nutrition Company | Amino Acid And Protein Hydrolysate Based Formulas With A Stable Emulsion System |
| US20140249214A1 (en) | 2013-03-01 | 2014-09-04 | Amarin Pharmaceuticals Ireland Limited | Co-administration of warfarin and ethyl eicosapentaenoate |
| WO2014134466A1 (en) | 2013-03-01 | 2014-09-04 | Amarin Pharmaceuticals Ireland Limited. | Co-administration of atorvastatin and ethyl eicosapentaenoic acid or a derivative thereof |
| US20140249225A1 (en) | 2013-03-01 | 2014-09-04 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidative modification of membrane polyunsaturated fatty acids |
| US20140249220A1 (en) | 2013-03-01 | 2014-09-04 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for reducing a fatty acid desaturation index in a subject in need thereof |
| US20140255537A1 (en) | 2013-03-11 | 2014-09-11 | Mead Johnson Nutrition Company | Nutritional Compositions Containing an Enriched Lipid Fraction and Uses Thereof |
| US9661874B2 (en) | 2013-03-11 | 2017-05-30 | Mead Johnson Nutrition Company | Nutritional compositions containing structured fat globules and uses thereof |
| US20140275252A1 (en) | 2013-03-14 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Methods of treating traumatic brain injury |
| US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
| US20140271907A1 (en) | 2013-03-14 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and krill oil and methods of use thereof |
| US10441560B2 (en) | 2013-03-15 | 2019-10-15 | Mochida Pharmaceutical Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| CN105592846A (zh) | 2013-03-15 | 2016-05-18 | 持田制药株式会社 | 用于治疗非酒精性脂肪性肝炎的组合物和方法 |
| US20140322314A1 (en) | 2013-04-29 | 2014-10-30 | Matinas Biopharma, Inc. | Omega-3 Fatty Acid Formulations for Use as Pharmaceutical Treatment |
| US20140357717A1 (en) | 2013-06-04 | 2014-12-04 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
| JPWO2015008849A1 (ja) | 2013-07-18 | 2017-03-02 | 持田製薬株式会社 | ω３脂肪酸の自己乳化組成物 |
| CN111888343A (zh) | 2013-07-18 | 2020-11-06 | 持田制药株式会社 | ω-3脂肪酸的自乳化组合物 |
| WO2015021141A1 (en) | 2013-08-06 | 2015-02-12 | Amarin Pharmaceuticals Ireland Limited | Methods of treating a cardiovascular disorder in a subject on apo-c3 modulating therapy |
| US20150051282A1 (en) | 2013-08-14 | 2015-02-19 | Amarin Pharmaceuticals Ireland Limited | Methods of treating a cardiovascular disorder and/or joint pain in a subject on glucosamine therapy |
| US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
| US20150073050A1 (en) | 2013-09-09 | 2015-03-12 | Amarin Pharmaceuticals Ireland Limited | Co-administration of omeprazole and eicosapentaenoic acid or a derivative thereof |
| WO2015053379A1 (en) | 2013-10-07 | 2015-04-16 | Mochida Pharmaceutical Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| WO2015066512A1 (en) | 2013-10-31 | 2015-05-07 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| HRP20192299T1 (hr) | 2014-04-11 | 2020-03-06 | Cymabay Therapeutics, Inc. | Liječenje nafld i nash |
| US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
| US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| WO2016117057A1 (ja) | 2015-01-21 | 2016-07-28 | 持田製薬株式会社 | ω３脂肪酸の自己乳化組成物 |
| WO2016117621A1 (ja) | 2015-01-21 | 2016-07-28 | 持田製薬株式会社 | ω３脂肪酸の自己乳化組成物 |
| WO2016140949A1 (en) | 2015-03-02 | 2016-09-09 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidative modification of membrane polyunsaturated fatty acids |
| US20170151202A1 (en) | 2015-09-09 | 2017-06-01 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
| US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| RS61403B1 (sr) | 2016-07-29 | 2021-02-26 | Kowa Co | Postupci prevencije kardiovaskularnih događaja u populacijama sa dislipidemijom sa rezidualnim rizikom |
| WO2018213663A1 (en) | 2017-05-19 | 2018-11-22 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
| US20190054054A1 (en) | 2017-08-15 | 2019-02-21 | Amarin Pharmaceuticals Ireland Limited | Methods reducing or preventing oxidation of high density lipoprotein (HDL) |
| US20190054058A1 (en) | 2017-08-15 | 2019-02-21 | Amarin Pharmaceuticals Ireland Limited | Methods of Treating or Preventing Bone Loss |
| US20190209506A1 (en) | 2018-01-09 | 2019-07-11 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of ldl or lipid membranes in a subject in need thereof |
| US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
| US20190275057A1 (en) | 2018-03-06 | 2019-09-12 | Amarin Pharmaceuticals Ireland Limited | Compositions and Methods for Lowering Triglycerides in a Subject with Reduced Kidney Function and Diabetes Mellitus |
| EA202190547A1 (ru) | 2018-08-17 | 2021-04-27 | Амарин Фармасьютикалз Айрлэнд Лимитед | Способы снижения потребности в реваскуляризации периферических артерий у субъекта, получающего лечение статинами |
| MA51766A (fr) | 2018-09-24 | 2020-12-16 | Amarin Pharmaceuticals Ie Ltd | Procédés de réduction du risque d'événements cardiovasculaires chez un sujet |
-
2013
- 2013-01-07 WO PCT/US2013/020526 patent/WO2013103958A1/en not_active Ceased
- 2013-01-07 AU AU2013207368A patent/AU2013207368A1/en not_active Abandoned
- 2013-01-07 US US13/735,660 patent/US9827219B2/en active Active
- 2013-01-07 EP EP13733751.5A patent/EP2800469B1/en not_active Revoked
- 2013-01-07 JP JP2014551390A patent/JP6307442B2/ja active Active
- 2013-01-07 ES ES13733751T patent/ES2891473T3/es active Active
-
2016
- 2016-11-11 AU AU2016256822A patent/AU2016256822B2/en active Active
-
2017
- 2017-10-24 US US15/791,885 patent/US10973796B2/en active Active
- 2017-11-09 JP JP2017216074A patent/JP6419927B2/ja active Active
-
2018
- 2018-11-06 AU AU2018260825A patent/AU2018260825B2/en active Active
-
2019
- 2019-04-18 US US16/388,052 patent/US20190240183A1/en not_active Abandoned
-
2020
- 2020-11-23 AU AU2020277100A patent/AU2020277100B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016256822A1 (en) | 2016-12-01 |
| JP2015503593A (ja) | 2015-02-02 |
| AU2016256822B2 (en) | 2018-08-09 |
| JP2018065816A (ja) | 2018-04-26 |
| US20130189355A1 (en) | 2013-07-25 |
| EP2800469A1 (en) | 2014-11-12 |
| EP2800469A4 (en) | 2015-07-29 |
| US9827219B2 (en) | 2017-11-28 |
| WO2013103958A1 (en) | 2013-07-11 |
| US20180042883A1 (en) | 2018-02-15 |
| US10973796B2 (en) | 2021-04-13 |
| AU2018260825B2 (en) | 2020-08-27 |
| AU2020277100A1 (en) | 2020-12-24 |
| HK1203764A1 (en) | 2015-11-06 |
| US20190240183A1 (en) | 2019-08-08 |
| AU2013207368A1 (en) | 2014-07-24 |
| EP2800469B1 (en) | 2021-08-25 |
| JP6419927B2 (ja) | 2018-11-07 |
| AU2018260825A1 (en) | 2018-11-22 |
| AU2020277100B2 (en) | 2022-10-06 |
| JP6307442B2 (ja) | 2018-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2891473T3 (es) | Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto | |
| US12171738B2 (en) | Compositions and methods for lowering triglycerides | |
| US20220323395A1 (en) | Methods of treating hypertriglyceridemia | |
| HK1203764B (en) | Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject |